Literature DB >> 19249770

The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice.

Annemarie C de Vries1, Jelle Haringsma, Richard A de Vries, Frank ter Borg, Nicole M Nagtzaam, Ewout W Steyerberg, Herman van Dekken, Ernst J Kuipers.   

Abstract

BACKGROUND: Surveillance of intestinal metaplasia (IM) of the gastric mucosa should be limited to patients at high risk of gastric cancer. Patients with extensive IM are at increased cancer risk; however, the intragastric extent of IM is usually unknown at the time of the initial diagnosis.
OBJECTIVE: To assess the predictive value of clinical, histologic, and serologic parameters for the intragastric extent of IM. DESIGN AND
SETTING: Prospective, multicenter study. PATIENTS: Eighty-eight patients with a previous diagnosis of IM of the gastric mucosa. INTERVENTION: Surveillance gastroscopy with extensive random biopsy sampling. MAIN OUTCOME MEASUREMENTS: Biopsy specimens were evaluated according to the Sydney classification system. In addition, serologic testing of Helicobacter pylori and cagA status, pepsinogens I and II, gastrin, and intrinsic factor antibodies was performed. The association between the available parameters and extensive IM was evaluated with logistic regression analysis.
RESULTS: In 51 patients (58%), IM was present in the biopsy specimens from at least 2 intragastric locations. The most important predictors of extensive IM were a family history of gastric cancer, alcohol use > or = 1 unit/d (1 glass, approximately 10 mL or 8 g ethanol), moderate or marked IM of the index biopsy specimen, and a pepsinogen I to II ratio < 3.0. A simple risk score based on these factors could identify extensive IM in 24 of 25 patients (sensitivity 96%). LIMITATION: A prospective cohort study should confirm the proposed risk stratification.
CONCLUSIONS: A risk score of clinical, histologic, and serologic parameters can predict extensive intragastric IM and may serve as a practical tool to select patients for surveillance endoscopy in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249770     DOI: 10.1016/j.gie.2008.08.041

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  14 in total

1.  Are we making progress in diagnosing and preventing gastrointestinal cancers?

Authors:  Jelle Haringsma; Nicoline C M van Heel; Ernst J Kuipers
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study.

Authors:  Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

Review 3.  Pathology of gastric intestinal metaplasia: clinical implications.

Authors:  Pelayo Correa; M Blanca Piazuelo; Keith T Wilson
Journal:  Am J Gastroenterol       Date:  2010-03       Impact factor: 10.864

Review 4.  Intestinal metaplasia and anastomotic recurrence of gastric carcinoma.

Authors:  Elroy Patrick Weledji; George Enow Orock; Marcelin Ngowe Ngowe
Journal:  J Gastrointest Oncol       Date:  2014-12

5.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

6.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

7.  Helicobacter pylori Infection and Gastric Adenocarcinoma.

Authors:  Pelayo Correa; M Blanca Piazuelo
Journal:  US Gastroenterol Hepatol Rev       Date:  2011-06

Review 8.  Gastric cancer: an infectious disease.

Authors:  M Blanca Piazuelo; Meira Epplein; Pelayo Correa
Journal:  Infect Dis Clin North Am       Date:  2010-12       Impact factor: 5.982

9.  Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy.

Authors:  Lisette G Capelle; Jelle Haringsma; Annemarie C de Vries; Ewout W Steyerberg; Katharina Biermann; Herman van Dekken; Ernst J Kuipers
Journal:  Dig Dis Sci       Date:  2010-12       Impact factor: 3.199

10.  High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.

Authors:  Sergejs Isajevs; Selga Savcenko; Inta Liepniece-Karele; Maria Blanca Piazuelo; Ilze Kikuste; Ivars Tolmanis; Aigars Vanags; Indra Gulbe; Linda Mezmale; Darhan Samentaev; Altynbek Tazedinov; Ramis Samsutdinov; Tatjana Belihina; Nurbek Igissinov; Marcis Leja
Journal:  Virchows Arch       Date:  2021-05-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.